BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 194 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $263,893 | +0.6% | 37,273 | -0.0% | 0.00% | 0.0% |
| Q2 2023 | $262,416 | +11.1% | 37,275 | +31.6% | 0.00% | 0.0% |
| Q1 2023 | $236,272 | -22.8% | 28,330 | +6.2% | 0.00% | -50.0% |
| Q4 2022 | $306,137 | -4.0% | 26,667 | +5.3% | 0.00% | 0.0% |
| Q3 2022 | $319,000 | +19.0% | 25,322 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $268,000 | -35.0% | 25,322 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $412,000 | -2.6% | 25,322 | -17.1% | 0.00% | 0.0% |
| Q4 2021 | $423,000 | +9.6% | 30,547 | +13.8% | 0.00% | 0.0% |
| Q3 2021 | $386,000 | -8.7% | 26,832 | +0.2% | 0.00% | 0.0% |
| Q2 2021 | $423,000 | +70.6% | 26,766 | +9.9% | 0.00% | +100.0% |
| Q1 2021 | $248,000 | +40.1% | 24,353 | +2.4% | 0.00% | 0.0% |
| Q4 2020 | $177,000 | +115.9% | 23,789 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $82,000 | -27.4% | 23,789 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $113,000 | +222.9% | 23,789 | +35.5% | 0.00% | – |
| Q1 2020 | $35,000 | +66.7% | 17,560 | +184.7% | 0.00% | – |
| Q4 2019 | $21,000 | +16.7% | 6,168 | 0.0% | 0.00% | – |
| Q3 2019 | $18,000 | -21.7% | 6,168 | 0.0% | 0.00% | – |
| Q2 2019 | $23,000 | -54.0% | 6,168 | 0.0% | 0.00% | – |
| Q1 2019 | $50,000 | 0.0% | 6,168 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $50,000 | +6.4% | 6,168 | 0.0% | 0.00% | – |
| Q3 2018 | $47,000 | +34.3% | 6,168 | 0.0% | 0.00% | – |
| Q2 2018 | $35,000 | +20.7% | 6,168 | 0.0% | 0.00% | – |
| Q1 2018 | $29,000 | -3.3% | 6,168 | 0.0% | 0.00% | – |
| Q4 2017 | $30,000 | +233.3% | 6,168 | +242.5% | 0.00% | – |
| Q3 2017 | $9,000 | -10.0% | 1,801 | 0.0% | 0.00% | – |
| Q2 2017 | $10,000 | -33.3% | 1,801 | 0.0% | 0.00% | – |
| Q1 2017 | $15,000 | +36.4% | 1,801 | 0.0% | 0.00% | – |
| Q4 2016 | $11,000 | +37.5% | 1,801 | 0.0% | 0.00% | – |
| Q3 2016 | $8,000 | +60.0% | 1,801 | 0.0% | 0.00% | – |
| Q2 2016 | $5,000 | 0.0% | 1,801 | 0.0% | 0.00% | – |
| Q1 2016 | $5,000 | -73.7% | 1,801 | 0.0% | 0.00% | – |
| Q4 2015 | $19,000 | +137.5% | 1,801 | +166.8% | 0.00% | – |
| Q3 2015 | $8,000 | – | 675 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |